nism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial showed that tolvaptan, combined with standard therapy, improved many heart failure signs and symptoms without serious adverse events. This study evaluated the hospital resource utilization associated with tolvaptan usage among heart failure (HF) patients with hyponatremia based on the EVEREST trial. METHODS: A cost offset model was constructed to evaluate the impact of tolvaptan on hospital resource utilization among HF patients. The Healthcare Cost and Utilization Project (HCUP) 2008 Nationwide Inpatient Sample (NIS) database was used to estimate hospitalization length of stay (LOS) and hospital cost, for HF-associated diagnosis related group hospitalizations (DRG) of adult patients (age Ն18 years). EVEREST trial data for patients with hyponatremia were used to estimate the reduction of LOS associated with tolvaptan vs. placebo. RESULTS: Among EVEREST trial HF patients with hyponatremia (Ͻ135 mEq/L), tolvaptan patients had a shorter hospitalization LOS than placebo patients (9.72 vs. 11.44 days, respectively), with a relative LOS reduction of 15%. 933,189 HF-associated DRG hospitalizations were identified from the HCUP NIS database. The mean LOS was 4.8 days with mean total hospital costs of $7,545, and mean daily hospital costs of $1,562. Using an inpatient tolvaptan treatment duration of 3 days with a daily wholesale acquisition cost of $250, the cost offset model estimated a LOS reduction among US HF hospitalizations of 0.73 days with a hospital cost reduction averaging $1,134 per HF admission. The cost neutral breakeven mean duration of tolvaptan inpatient therapy is 4.54 days. CONCLUSIONS: Based on the EVEREST trial, tolvaptan is associated with a shorter hospitalization LOS than placebo among hyponatremic HF patients, resulting in an estimated mean hospital cost reduction of $1,134 per admission in the US.
OBJECTIVES: Anti-platelet therapy is recommended for patients with a history of acute coronary syndrome (ACS), including aspirin and clopidogrel or prasugrel. Ticagrelor is a new anti-platelet agent, not yet available on the market; in clinical trials ticagrelor was associated with significantly higher rates of dyspnea than clopidogrel. ACS patients presenting with dyspnea require additional medical attention to rule out possible heart failure which may lead to increased costs. This study used real world data to quantify the direct medical costs of dyspnea among patients with a history of ACS. METHODS: Patients with an emergency room (ER) visit for dyspnea (ICD-9-CM 786.0x) in 2008 or 2009 were identified using the Mar-ketScan Research Databases ® . Patients were required to have six months continuous medical enrollment prior to the ER visit, with a history of ACS (ICD-9-CM 410.xx, 411.1x). Procedure utilization and expenditures were evaluated for the ER visit and associated outpatient services, as well as the proportion of ER visits which led to an inpatient stay. Costs were adjusted to 2009 US dollars. RESULTS: A total of 8,433 ER visits for dyspnea were identified. The average cost per dyspnea episode was $6,958, of which $1,621 was outpatient costs associated with the ER visit (SDϭ $3,269). Along with physician services, assessment of dyspnea often included electrocardiogram (71.3%), chest radiograph (75.9%) and, occasionally, a B-type natriuretic peptide (BNP) test (14.9%) or chest CAT scan (12.2%). These procedures constituted 35.1% of the average outpatient costs. Over a quarter (25.8%) of dyspnea ER visits led to an inpatient stay, with an average cost of $20,693 per patient. CONCLUSIONS: Dyspnea is a significant event associated with high medical resource utilization and hospital costs. Considering that the increased risk of dyspnea for ticagrelor is well-documented, these costs may be important to health plan decision makers when evaluating costs associated with each anti-platelet therapy.
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CHARACTERIZATION OF COSTS ASSOCIATED WITH STROKE REHABILITATION: A REVIEW OF THE LITERATURE
Sacco P, Johnson J, Verma A Novartis Pharmaceuticals, East Hanover, NJ, USA OBJECTIVES: The economic burden of stroke is approximately 3% of total healthcare costs or 0.3-1.8% of Gross National Product in developed countries. Identifying what drives value and cost in post-stroke care can advance development of costeffective interventions that improve long term outcomes. This review characterizes costs associated with stroke rehabilitation. METHODS: PUBMED was searched between 2000 and 2010; search terms included stroke, rehabilitation, costs, pharmacoeconomic and price. Countries of interest were Canada, China, France, Germany, Italy, Japan, Spain, UK, and US. Data were synthesized qualitatively. RESULTS: Of 941 abstracts, 28 met inclusion criteria. Manual searching of retrieved papers and websites yielded 4 additional sources. The main factor determining cost was the country in which the study was conducted. Patients with severe stroke are routinely considered for rehabilitation; those with mild-moderate stroke (60 -75% of stroke survivors) are typically discharged directly to home. Of all stroke patients, only 10-15% receive rehabilitation. Countries spending a large proportion on long term care for patients post-stroke, spent proportionally less on inpatient care. Inpatient costs account for an average of 76% of costs in the first year following stroke. Rehabilitation costs are often included in inpatient costs, with the majority of rehabilitation costs occurring in year 1 (82% for patients with hemiparesis; 67% for patients without hemiparesis). Evidence suggests that stroke unit care improves long term outcomes as compared to conventional treatment. There are few data on indirect costs despite the recognition that they are likely to be substantial. CONCLUSIONS: Cost studies in stroke are heterogeneous, lack specific economic data and rarely include long term rehabilitation cost of care. Future studies should aim to differentiate 1) direct costs of various rehabilitation services, 2) location for provision of rehabilitation services, and 3) indirect costs to demonstrate cost-effectiveness and value of rehabilitation on long term outcomes.
PCV40 COST AND PRACTICE OF TREATMENT OF ACUTE ISCHEMIC STROKE IN REAL WORLD SETTINGS IN RUSSIA
Vorobyev P, Bezmelnitsyna L, Borisenko O Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia OBJECTIVES: To evaluate typical practice and cost of treatment patients with acute ischemic stroke in leading medical hospitals in Russia, to compare treatment patterns and cost of treatment in "real world settings" and according to national standard of care in stroke. METHODS: Retrospective analysis of case records of patients with acute ischemic stroke. Treatment patterns in "real world settings" and according to national standard of care in stroke were compared. Direct cost of treatment was estimated from state health care system point of view. RESULTS: Data from 140 case records was retrieved. Significant inconsistencies in the list of medicines between protocol of care and typical practice have been identified. Particularly, the frequency prescription of anticonvulsants and myorelaxants in real world settings was lower than in protocol. Low frequency of psychological (0%-in typical practice, 80% -in protocol) and rehabilitation methods of treatment (33%in typical practice, 70-80% -in protocol) was revealed. Patients also didn't receive prophylactics of tromboembolism (6% -in typical practice, 80% -in protocol). Average total cost of treatment of one patient with ischemic stroke in typical practice was 905 dollars (302 dollars -cost of drug therapy, 187 dollars -cost of medical diagnostic and therapeutic services, 416 dollars -accommodation costs). Average period of inpatient stay was 20 days. Average total cost of treatment of one patients with ischemic stroke according to the protocol was 1 446 dollars (322 dollars -cost of drug therapy, 686 dollars -cost of diagnostic and therapeutic services, 438 dollars -accommodation costs). CONCLUSIONS: Significant inconsistencies of management patterns in patients with ischemic stroke in typical practice and national standard have been revealed. Direct costs of inpatient care in typical practice are approximately twice lower than costs calculated from national protocol of care.
PCV41 AN ESTIMATE OF SOCIETAL MONETARY BENEFITS OF SIMVASTATIN IN CANADA
Thanh NX, Chuck A, Ohinmaa A, Jacobs P Institute of Health Economics, Edmonton, AB, Canada OBJECTIVES: To estimate the societal monetary benefit of simvastatin to three separate groups: 1) developing manufacturer (DM), 2) generic manufacturer (GM) and 3) society. METHODS: The monetary benefits for DM and GM were estimated by calculating annual revenues based on IMS sales data between 2000 and 2009. We used a dynamic Markov model to estimate the monetary benefits for society over the same time period in terms of cost avoidance associated with prevented cardiovascular events including stroke and myocardial infarction and lost productivity due to disability and premature death in the working population. Input estimates for dynamic populations were derived from the IMS sales data. Input estimates for prevented adverse events and costs were derived from systematic review and meta-analysis when possible. Input estimates for reduction in health care utilization and disability days were estimated from multivariate regressions using data in the 2005 Canadian Community Health Survey. All costs and benefits were expressed in 2010 Canadian dollars. RESULTS: The cumulative societal monetary benefit of simvastatin over the 10 years (from 2000 to 2009) was estimated at $4 billion. Of this, DM accounted for 23%, GM 31%, and society 46% (health care 34% and productivity losses 12%). Of note, the trend was different among the three parties. The benefit to DM levelled out from 2002 when the pharmaceutical was no longer under patent protection when the benefit to GM started to increase. The benefit to society increased consistently over the study period. CONCLUSIONS: The results indicate that simvastatin is associated with significant benefit to both society and industry, including DM and GM. A comprehensive evaluation of benefits of pharmaceutical innovation should therefore consider benefits to all beneficiaries.
PCV42 A DECISION MODELING APPROACH TO EVALUATE THE COST-EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS WITH PLANNED PERCUTANEOUS CORONARY INTERVENTION
in lifetime costs and utilities of $17,208 and 10.4124 QALYs compared with $16,780 and 10.4057 QALYs for prasugrel therapy. The ICER for clopidogrel was $63,840/ QALYs. The acceptability curve showed that prasugrel was not likely cost-effective with Ͼ80% certainty at any WTP threshold. One-way sensitivity analyses (WTP decision threshold: $100,000/QALY) showed that prasugrel is the most cost-effective strategy when probability of MI is increased by Ͼ12%, probability of bleeding is decreased by Ͼ24%, and disutility associated with MI is Ͼ0.1634. When only patients with variant CYP2C19 were considered, the ICER was found to be $2,313,333/ QALY for clopidogrel. CONCLUSIONS: Inconclusive results indicate that there is no benefit in prescribing one therapy over the other for the entire patient population. CYP2C19 polymorphism should be given consideration during the decision making process. For the base-case scenario, prasugrel therapy was the preferred strategy in patients with variant CYP2C19.
